FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4211179877> ?p ?o ?g. }

• W4211179877 abstract "Background Adjuvant chemotherapy improves survival in premenopausal and postmenopausal women with early breast cancer. Taxanes are highly active chemotherapy agents used in metastatic breast cancer. Review authors examined their role in early breast cancer. This review is an update of a Cochrane Review first published in 2007. Objectives To assess the effects of taxane‐containing adjuvant chemotherapy regimens for treatment of women with operable early breast cancer. Search methods For this review update, we searched the Specialised Register of the Cochrane Breast Cancer Group, MEDLINE, Embase, CENTRAL (2018, Issue 6), the WHO International Clinical Trials Registry Platform (ICTRP), and ClinicalTrials.gov on 16 July 2018, using key words such as 'early breast cancer' and 'taxanes'. We screened reference lists of other related literature reviews and articles, contacted trial authors, and applied no language restrictions. Selection criteria Randomised trials comparing taxane‐containing regimens versus non‐taxane‐containing regimens in women with operable breast cancer were included. Studies of women receiving neoadjuvant chemotherapy were excluded. Data collection and analysis Two review authors independently extracted data and assessed risk of bias and quality of the evidence using the GRADE approach. Hazard ratios (HRs) were derived for time‐to‐event outcomes, and meta‐analysis was performed using a fixed‐effect model. The primary outcome measure was overall survival (OS); disease‐free survival (DFS) was a secondary outcome measure. Toxicity was represented as odds ratios (ORs), and quality of life (QoL) data were extracted when present. Main results This review included 29 studies (27 full‐text publications and 2 abstracts or online theses). The updated analysis included 41,911 randomised women; the original review included 21,191 women. Taxane‐containing regimens improved OS (HR 0.87, 95% confidence interval (CI) 0.83 to 0.92; high‐certainty evidence; 27 studies; 39,180 women; 6501 deaths) and DFS (HR, 0.88, 95% CI 0.85 to 0.92; high‐certainty evidence; 29 studies; 41,909 women; 10,271 reported events) compared to chemotherapy without a taxane. There was moderate to substantial heterogeneity across studies for OS and DFS (respectively). When a taxane‐containing regimen was compared with the same regimen without a taxane, the beneficial effects of taxanes persisted for OS (HR 0.84, 95% CI 0.77 to 0.92; P < 0.001; 7 studies; 10,842 women) and for DFS (HR 0.84, 95% CI 0.78 to 0.90; P < 0.001; 7 studies; 10,842 women). When a taxane‐containing regimen was compared with the same regimen with another drug or drugs that were substituted for the taxane, a beneficial effect was observed for OS and DFS with the taxane‐containing regimen (OS: HR 0.80, 95% CI 0.74 to 0.86; P < 0.001; 13 studies; 16,196 women; DFS: HR 0.83, 95% CI 0.78 to 0.88; P < 0.001; 14 studies; 16,823 women). Preliminary subgroup analysis by lymph node status showed a survival benefit with taxane‐containing regimens in studies of women with lymph node‐positive disease only (HR 0.83, 95% CI 0.78 to 0.88; P < 0.001; 17 studies; 22,055 women) but less benefit in studies of women both with and without lymph node metastases or with no lymph node metastases. Taxane‐containing regimens also improved DFS in women with lymph node‐positive disease (HR 0.84, 95% CI 0.80 to 0.88; P < 0.001; 17 studies; 22,055 women), although the benefit was marginal in studies of women both with and without lymph node‐positive disease (HR 0.95, 95% CI 0.88 to 1.02; 9 studies; 12,998 women) and was not apparent in studies of women with lymph node‐negative disease (HR 0.99, 95% CI 0.86 to 1.14; 3 studies; 6856 women). Taxanes probably result in a small increase in risk of febrile neutropenia (odds ratio (OR) 1.55, 95% CI 0.96 to 2.49; moderate‐certainty evidence; 24 studies; 33,763 women) and likely lead to a large increase in grade 3/4 neuropathy (OR 6.89, 95% CI 3.23 to 14.71; P < 0.001; moderate‐certainty evidence; 22 studies; 31,033 women). Taxanes probably cause little or no difference in cardiotoxicity compared to regimens without a taxane (OR 0.87, 95% CI 0.56 to 1.33; moderate‐certainty evidence; 23 studies; 32,894 women). Seven studies reported low‐quality evidence for QoL; overall, taxanes may make little or no difference in QoL compared to chemotherapy without a taxane during the follow‐up period; however, the duration of follow‐up differed across studies. Only one study, which was conducted in Europe, provided cost‐effectiveness data. Authors' conclusions This review of studies supports the use of taxane‐containing adjuvant chemotherapy regimens, with improvement in overall survival and disease‐free survival for women with operable early breast cancer. This benefit persisted when analyses strictly compared a taxane‐containing regimen versus the same regimen without a taxane or the same regimen with another drug that was substituted for the taxane. Preliminary evidence suggests that taxanes are more effective for women with lymph node‐positive disease than for those with lymph node‐negative disease. Considerable heterogeneity across studies probably reflects the varying efficacy of the chemotherapy backbones of the comparator regimens used in these studies. This review update reports results that are remarkably consistent with those of the original review, and it is highly unlikely that this review will be updated, as new trials are assessing treatments based on more detailed breast cancer biology." @default.
• W4211179877 created "2022-02-13" @default.
• W4211179877 creator A5015006267 @default.
• W4211179877 creator A5037026312 @default.
• W4211179877 creator A5043048253 @default.
• W4211179877 creator A5058878624 @default.
• W4211179877 creator A5059903550 @default.
• W4211179877 creator A5067071864 @default.
• W4211179877 date "2019-09-02" @default.
• W4211179877 modified "2023-10-03" @default.
• W4211179877 title "Taxanes for adjuvant treatment of early breast cancer" @default.
• W4211179877 cites W1484929874 @default.
• W4211179877 cites W1575220727 @default.
• W4211179877 cites W1612286138 @default.
• W4211179877 cites W1757407923 @default.
• W4211179877 cites W1904314523 @default.
• W4211179877 cites W1910241730 @default.
• W4211179877 cites W1924346446 @default.
• W4211179877 cites W1961026612 @default.
• W4211179877 cites W1964409276 @default.
• W4211179877 cites W1973936121 @default.
• W4211179877 cites W1980544879 @default.
• W4211179877 cites W1980876405 @default.
• W4211179877 cites W1983212964 @default.
• W4211179877 cites W1991294695 @default.
• W4211179877 cites W2001133390 @default.
• W4211179877 cites W2009189135 @default.
• W4211179877 cites W2009379958 @default.
• W4211179877 cites W2011567222 @default.
• W4211179877 cites W2014179352 @default.
• W4211179877 cites W2014566389 @default.
• W4211179877 cites W2015921398 @default.
• W4211179877 cites W2016106724 @default.
• W4211179877 cites W2046335090 @default.
• W4211179877 cites W2048553013 @default.
• W4211179877 cites W2054887029 @default.
• W4211179877 cites W2055468688 @default.
• W4211179877 cites W2062995142 @default.
• W4211179877 cites W2063880519 @default.
• W4211179877 cites W2066514716 @default.
• W4211179877 cites W2075213874 @default.
• W4211179877 cites W2075642745 @default.
• W4211179877 cites W2078110114 @default.
• W4211179877 cites W2084370697 @default.
• W4211179877 cites W2087692177 @default.
• W4211179877 cites W2088095316 @default.
• W4211179877 cites W2096334407 @default.
• W4211179877 cites W2096818458 @default.
• W4211179877 cites W2097996372 @default.
• W4211179877 cites W2098333537 @default.
• W4211179877 cites W2099562503 @default.
• W4211179877 cites W2099934920 @default.
• W4211179877 cites W2105851752 @default.
• W4211179877 cites W2109497907 @default.
• W4211179877 cites W2111675043 @default.
• W4211179877 cites W2114397636 @default.
• W4211179877 cites W2114402477 @default.
• W4211179877 cites W2115432999 @default.
• W4211179877 cites W2115568598 @default.
• W4211179877 cites W2116044878 @default.
• W4211179877 cites W2117239059 @default.
• W4211179877 cites W2119438951 @default.
• W4211179877 cites W2120639027 @default.
• W4211179877 cites W2121940479 @default.
• W4211179877 cites W2125729597 @default.
• W4211179877 cites W2125835228 @default.
• W4211179877 cites W2127232551 @default.
• W4211179877 cites W2127501098 @default.
• W4211179877 cites W2135800076 @default.
• W4211179877 cites W2136655134 @default.
• W4211179877 cites W2140354367 @default.
• W4211179877 cites W2141056749 @default.
• W4211179877 cites W2144124503 @default.
• W4211179877 cites W2145719360 @default.
• W4211179877 cites W2147105278 @default.
• W4211179877 cites W2147660572 @default.
• W4211179877 cites W2149876820 @default.
• W4211179877 cites W2153158488 @default.
• W4211179877 cites W2153553648 @default.
• W4211179877 cites W2156556190 @default.
• W4211179877 cites W2168846361 @default.
• W4211179877 cites W2168993400 @default.
• W4211179877 cites W2193011618 @default.
• W4211179877 cites W2205210173 @default.
• W4211179877 cites W2229395424 @default.
• W4211179877 cites W2243148137 @default.
• W4211179877 cites W2245717366 @default.
• W4211179877 cites W2249906557 @default.
• W4211179877 cites W2268094021 @default.
• W4211179877 cites W2302883456 @default.
• W4211179877 cites W2318398168 @default.
• W4211179877 cites W2323000147 @default.
• W4211179877 cites W2336136961 @default.
• W4211179877 cites W2503852651 @default.
• W4211179877 cites W2560771717 @default.
• W4211179877 cites W2585390257 @default.
• W4211179877 cites W2586447645 @default.
• W4211179877 cites W2591353023 @default.
• W4211179877 cites W2599332339 @default.
• W4211179877 cites W2614482856 @default.

• next